TNF-α levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy

Andıran, Nesibe; Yordam, Nurşen

doi:10.1016/j.ghir.2007.01.002

Cited by 28 publications

(29 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The IL-10 cells may inhibit the production of Th1 cytokines (Moore, de Waal Malefyt, Coffman, & O'Garra, 2001) leading to the prevalence of Th2 cells. IGF-I may induce a shift from the production of Th1 The rhGH therapy is a recognised procedure for enhancing immune function in GH deficient populations (Crist et al, 1987;Sneppen et al, 2002;Serri et al, 1999;Andiran and Yordam, 2007), and our data suggest that a dose of 1mg/day for seven days may potentiate immune function of healthy young males through the significant increase in the release of IL10 by CD4 + T lymphocytes.…”

Section: Discussionmentioning

confidence: 50%

“…As previously mentioned, long-term therapy with rhGH administration in GHD children effectively reduces TNF-α level in these patients (Andiran & Yordam, 2007).…”

Section: Introductionmentioning

confidence: 68%

“…In GHD patients suffering from hypopituitarism, they demonstrate immunological impairment parameters such as increased basal plasma levels of tumour necrosis factor-(TNF -220%) and IL-6 by 340% (Serri et al, 1999). Other studies have shown that blood TNF-α levels are significantly higher in children with GHD than the controls, and long-term therapy with rhGH was effective at reducing such levels (Andiran & Yordam, 2007). In vitro administration of exogenous GH has been shown to improve a variety of immune cell functions including B lymphocyte antibody production and responses (Kimata & Yoshida, 1994), NK activity (Stephenson, Lee, Bailey, Shepherd, & Melling, 1991), macrophage activity (Gaytan, et al, 1994), T lymphocytes and neutrophil functions (Fu, et al, 1992).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of immune function after short-term administration of recombinant human growth hormone in healthy young males

et al. 2010

View full text Add to dashboard Cite

It is reported that in both elite and recreational athletes Growth Hormone (GH) is the most commonly used drug aimed at improving sport performance. Aim: The purpose of the present study was to evaluate the immunomodulatory effects of short-term administration of recombinant human GH (rhGH) in healthy young males. NK cell number, activity and phenotype, T cell number, cytokine production of IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ and CD4 + /CD8 + ratio with particular attention to the possible correlation to IGF-I production were investigated. Methodology: 30 healthy young males (27 ± 9 yrs) were randomly assigned to either placebo (n = 15) or drug (rhGH) 1mg/day groups (n = 15) with daily injection for seven days. IGF-I serum concentration and flow cytometry data were generated at baseline (day 0) and days 8, 15, 22 and 29 post injection. Data was analysed using a General Linear Model with repeated measures with a Bonferroni correction factor and significance set at p≤0.05. Results: The T cell cytokine secretion profile indicated a Th1 -Th2 shift. Interestingly, a significant difference (p≤0.05) of IL-10 mean fluorescence is noted from day 15 (P= 35.14; ± 19.93, rhGH = 26.63; ± 16.39) to day 22 (P= 61.32; ± 20.41, rhGH= 74.99; ± 46.91) and to day 29 (P= 101.98; ± 67.25, rhGH= 107.74; ± 122.58). Serum IGF-I concentration (ng/mL) increased significantly (p≤0.01) on day 8 (0.48 ± 0.78) after injections compared to baseline (0.31 ± 0.07) as well at day 15 (0.33 ± 0.06), 22 (0.29 ± 0.05) and 29 (0.29 ± 0.06). In conclusion, the cytokine secretion spectrum is affected by short-term rhGH administration in healthy young males being suggested to have induced CD4 + T lymphocytes production of IL-10.

show abstract

Section: Discussionmentioning

confidence: 50%

“…As previously mentioned, long-term therapy with rhGH administration in GHD children effectively reduces TNF-α level in these patients (Andiran & Yordam, 2007).…”

Section: Introductionmentioning

confidence: 68%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of immune function after short-term administration of recombinant human growth hormone in healthy young males

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In GHD patients, an increase of IL-6 levels has been reported, independently of BMI, and of TNF-α values, which decreased after GH replacement therapy [55,56]. Some Authors have demonstrated an increase of leptin values in GHD patients [57,58].…”

Section: B Lipid Metabolismmentioning

confidence: 98%

Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]

et al. 2015

View full text Add to dashboard Cite

Abstract. Adult growth hormone deficiency (GHD) is a well defined clinical condition, which is characterized by abnormal body composition, impaired physical activity and decreased quality of life. In addition, in recent years, growing interest has been shown towards cardiovascular risks in adult patients affected by GHD. In this regard, GHD is widely known to be associated with increased mortality, likely due to the increase of risk factors, such as central obesity, impaired lipid and glucose profiles and other less-known risk factors, such as inflammatory cytokines, endothelial dysfunction and oxidative stress. However, very few papers have recently discussed this topic. In this review, the aim is to clarify this issue by discussing evidence regarding the effects of adult GHD on metabolic and cardiovascular profiles.

show abstract

“…GH has been found to stimulate TNF α release in adults and children [5] [6]; however, there has been inconsistent documentation within the literature [7]- [9]. Research in hypophysectomized rats demonstrate a significant reduction in in vitro macrophage production of TNF α after stimulation with lipopolysaccharide [3].…”

Section: Introductionmentioning

confidence: 99%

Relationship between Growth Hormone and Cytokines in Short Children Undergoing Growth Hormone Stimulation Testing

Tafuri¹,

Dixon²,

Markarian³

et al. 2015

IJCM

View full text Add to dashboard Cite

Background: The relationship between growth hormone (GH) and cytokines remains unclear. Several studies have suggested that GH increases tumor necrosis factor (TNF)-α production in both children and adults. However, a number of studies have demonstrated a negative correlation between GH and TNF α. The aim of this study is to explore the relationship between endogenous GH secretion and certain pro and anti-inflammatory cytokines in short children undergoing GH stimulation testing for evaluation for GH deficiency. Methods: Plasma growth hormone, TNF α, CRP, IL-6, IL1-β, IL-4 and IL-10 levels are obtained at baseline and every 30 minutes for 150 minutes following two provocative agents (clonidine, and either arginine or glucagon). Results: Among the 23 children, 7 are found to be GH deficient. No significant differences in baseline TNF α levels are found between GH deficient and GH sufficient children. No correlation is identified between TNF α levels and GH levels during stimulation testing. Furthermore, no relationship is found between GH and pro-inflammatory cytokines or GH and anti-inflammatory cytokines. Conclusion: Our results do not demonstrate an acute relationship between endogenous GH secretion and the cytokines examined.

show abstract

TNF-α levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy

Cited by 28 publications

References 30 publications

Assessment of immune function after short-term administration of recombinant human growth hormone in healthy young males

Assessment of immune function after short-term administration of recombinant human growth hormone in healthy young males

Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]

Relationship between Growth Hormone and Cytokines in Short Children Undergoing Growth Hormone Stimulation Testing

Contact Info

Product

Resources

About